Abstract

AN UPDATED REVIEW ON MEDICATION USED DURING COVID-19

Mittal Gaurav* and Niranjan Pankaj S.

ABSTRACT

Due to the limited evidence available on effective treatment options available, severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) has a great impact in terms of morbidity and mortality. The economic impact is still to be assessed. The main objective of this article is to review the evidence for the various treatment options available, and also to consider the future of this global pandemic, and to identify some potential options that could revolutionize the treatment of COVID-19. The potential severity of this COVID-19 and its deadly complications requires urgent development of novel therapeutic agents to both prevent and treat COVID-19. Although There are several COVID-19 vaccines validated for use by WHO. The first mass vaccination programme started in early December 2020. In this review, we aim to highlight the available treatment options for COVID-19 based on current clinical evidence will be discussed here. These include chloroquine, hydroxychloroquine anti-viral agents (remdesivir, ribavirin, lopinavir-ritonavir, favipiravir, oseltamivir, umifenovir), immunomodulatory agents (tocilizumab, interferons, plasma transfusions), and adjunctive agents (azithromycin, corticosteroids), among other miscellaneous agents.

Keywords: COVID-19, Treatment, corona varients, New drugs, COVID Vaccines, SARS-CoV-2, WHO.